This afternoon we watched Ascendis Pharma A/S rise 2.5% to a price of $140.42 per share. The Mid-Cap Pharmaceutical company is now trading -28.17% below its average target price of $195.5. Analysts have set target prices ranging from $164.96 to $276.94 per share for Ascendis Pharma A/S, and have given the stock an average rating of buy.
Ascendis Pharma A/S has an average level of shares sold short, at 8.8% of its total share float. The stock's short ratio (also called days to cover) is 12.86. Only 0.76% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Institutional investors own 108.1% of Ascendis Pharma A/S's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Ascendis Pharma A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | RA Capital Management, L.P. | 17% | 10,108,400 | $1,419,421,509 |
| 2024-06-30 | Westfield Capital Management Co LP | 9% | 4,962,824 | $696,879,736 |
| 2024-06-30 | FMR, LLC | 8% | 4,922,555 | $691,225,164 |
| 2024-06-30 | Artisan Partners Limited Partnership | 7% | 4,295,029 | $603,107,964 |
| 2024-06-30 | Avoro Capital Advisors LLC | 7% | 4,196,661 | $589,295,129 |
| 2024-06-30 | Janus Henderson Group PLC | 7% | 3,918,813 | $550,279,714 |
| 2024-06-30 | Wellington Management Group, LLP | 4% | 2,612,856 | $366,897,234 |
| 2024-06-30 | Capital International Investors | 4% | 2,104,298 | $295,485,521 |
| 2024-06-30 | Franklin Resources, Inc. | 4% | 2,084,851 | $292,754,773 |
| 2024-06-30 | Price (T.Rowe) Associates Inc | 3% | 1,784,148 | $250,530,058 |
